White paper consultation - List of stakeholder submissions
Canada's commitment to open government is part of the federal government's efforts to foster greater openness and transparency to provide Canadians with more opportunities to learn about and participate in government and, at the same time, create a more efficient and responsive government.
If you would like to receive any of the submissions listed below, please specify which submissions and contact us at: rmod_stakeholders-intervenants_dgro@hc-sc.gc.ca
| Date received | Name | Organisation |
|---|---|---|
| 2017-04-28 | Yan Xu, M.D., RCPSC Internal Medicine Resident | Department of Medicine, University of Toronto |
| 2017-04-30 | Laura King, Head of Regulatory Affairs & Global Drug Development | Novartis Pharmaceuticals Canada Inc. |
| 2017-05-14 | Michael Kruse, Executive Director | Bad Science Watch |
| 2017-05-15 | Jamie Scott, MD, PhD | Professor & Canada Research Chair, Simon Fraser University |
| 2017-05-17 | Kristin Willemsen, Director of Scientific & Regulatory Affairs | Consumer Health Products (CHP) Canada |
| 2017-05-17 | Angus Campbell | individual submission |
| 2017-05-19 | Elizabeth Borek | individual submission |
| 2017-05-19 | Jamie Falk, PharmD, Assistant Professor | College of Pharmacy, University of Manitoba |
| 2017-05-19 | Anne & Paul Caron | individual submission |
| 2017-05-19 | Jane Turner, President (sent by Devika Krishnan) | REACH Community Health Centre |
| 2017-05-19 | Michael Furman | University of Cambridge, UK |
| 2017-05-19 | Margot Duley | individual submission |
| 2017-05-20 | Andrée Crépeau, | individual submission |
| 2017-05-20 | Dr. Joel Lexchin, MD, Professor Emeritus, et.al. Author's submission undersigned by 120 individual academics, health researchers, health professionals, and/or patient advocates. |
School of Health Policy and Management, Faculty of Health, York University Signatories' organisational affiliation(s) included. |
| 2017-05-20 | Jane Macdonald | individual submission |
| 2017-05-21 | Matt Oxman | Informed Health Choices |
| 2017-05-21 | John-Jose Nunez, MD | University of British Columbia |
| 2017-05-23 | Michael West, Professor of Medicine & Assistant Dean Research - Clinical Trials | Dalhousie Medical School, Dalhousie University |
| 2017-05-23 | Dan Ryder, Associate Professor | Irving K. Barber School of Arts and Sciences, University of British Columbia |
| 2017-05-24 | Brian Lewis, President & CEO | MEDEC |
| 2017-05-24 | Janet Currie (PhD Candidate, UBC), et.al. Author's submission undersigned by 5 individual academics, health researchers, health professionals, and/or patient advocates. |
Independent Voices for Safe and Effective Drugs (IVSED) Signatories' organisational affiliation(s) included. |
| 2017-05-25 | Angela Spelsberg | Chair, Working Group on Health, Transparency International Germany |
| 2017-05-25 | Aled Edwards, Chief Executive | Structural Genomics Consortium (SGC) |
| 2017-05-25 | Tara Federici, VP - Technology and Regulatory Affairs, | AdvaMed (Advanced Medical Technology Association) |
| 2017-05-25 | Marleine El-Ghazal (for Keith McIntosh), | Innovative Medicines Canada (IMC) |
| 2017-05-25 | Anne Wilkie, VP - Scientific & Regulatory Affairs | Canadian Generic Pharmaceutical Association (CGPA) |
| 2017-05-25 | Katie Gibbs, Executive Director | Evidence for Democracy |
| 2017-05-25 | Sarah Jennings, Acting Manager, Professional and Regulatory Affairs | National Association of Pharmacy Regulatory Authorities (NAPRA) |
| 2017-05-25 | Rikesh Gandhi, Manager, Regulatory Affairs (on behalf of: Christopher Fredric, Associate Director, Regulatory Affairs) | Alexion Pharma Canada |
| 2017-05-25 | Maggy Mouradian, Established Products & Regulatory Operations Manager | Boehringer Ingelheim (Canada) Ltd. |
| 2017-05-26 | Margaret E. McCarthy, Executive Director, | Collaboration for Research Integrity and Transparency (CRIT), Yale Law School |
| 2017-05-26 | Donald Elrick, Director Regulatory Affairs, Immunology | Janssen Inc. |
| 2017-05-26 | Lesia Babiak, Executive Director, Worldwide Government Affairs & Policy (Canada) | Johnson & Johnson |
| 2017-05-26 | Sally Prawdzik, Director, Regulatory Policy Innovation | Johnson & Johnson |
| 2017-05-26 | Corina Voda, Regulatory Affairs Project Manager | AbbVie Corporation |
| 2017-06-09 (originally submitted: 2017-05-26) | Terence Young, Chair | Drug Safety Canada |
| 2017-05-26 | Rocelyn DelCarmen, Director, Regulatory Affairs and Quality Assurance | AstraZeneca Canada Inc. |
| 2017-05-26 | Kevin Anderson (on behalf of Dr. Khaled El Emam) | Pharmaceutical Users Software Exchange (PhUSE), |
| 2017-05-26 | Stephanie Croley, Regulatory Affairs Specialist | Purdue Pharma (Canada) |
| 2017-05-26 | Leslie Holt | individual submission |
| 2017-05-26 | Sandra Wainwright, Executive Director, Regulatory Affairs | Merck Canada Inc. |
| 2017-05-26 | Andrew Casey, President & CEO, with comments from Ron Boch | BIOTECanada |
| 2017-05-26 | Arshia Ghani, Associate Director, Regulatory Affairs | Pfizer Canada Inc. |
| 2017-05-26 | Khaled El Emam, President, & Hazel Nicholls | Privacy Analytics |
| 2017-05-31 | Sylvie Leblanc | individual submission |
Learn about how Health Canada will handle information from meetings and correspondence with stakeholders related to implementation of its proposal for public release of clinical information in drug submissions and medical device applications.
Page details
- Date modified: